Evidence map›Paper›PMID 42187449›Full record

ArticleBiosensors2026

Cell-Based Luciferase Assay for Testing SARS-CoV-2 3CL Protease Inhibitors.

Dmitry N Shcherbakov, Ekaterina D Mordvinova, Vadim O Trufanov, Natalia V Volkova, Yulia V Meshkova, Maria K Marenina, Anna V Zaykovskaya, Ekaterina A Volosnikova, Sophia S Borisevich, Svetlana V Belenkaya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dmitry N ShcherbakovState Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Novosibirsk, Russia.ORCID 0000-0001-8023-4453
Ekaterina D MordvinovaState Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Novosibirsk, Russia.
Vadim O TrufanovState Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Novosibirsk, Russia.
Natalia V VolkovaState Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Novosibirsk, Russia.ORCID 0000-0001-5010-9424
Yulia V MeshkovaN. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Academician Lavrent'ev Ave. 9, 630090 Novosibirsk, Russia.ORCID 0000-0002-5935-2540
Maria K MareninaN. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Academician Lavrent'ev Ave. 9, 630090 Novosibirsk, Russia.ORCID 0000-0002-9500-1713
Anna V ZaykovskayaState Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Novosibirsk, Russia.
Ekaterina A VolosnikovaState Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Novosibirsk, Russia.
Sophia S BorisevichSynchrotron Radiation Facility, Siberian Circular Photon Source "SKlF" Boreskov Institute Catalysis, Siberian Branch of the Russian Academy of Sciences, Nikolskiy pr-t, 1, Koltsovo, 630559 Novosibirsk, Russia.ORCID 0000-0001-8481-0470
Svetlana V BelenkayaState Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Novosibirsk, Russia.ORCID 0000-0002-3883-6335

Funding

Russian Science Foundation 24-75-00117
6 · The paper itself

Abstract

A cell-based screening system for viral protease inhibitors was developed using firefly luciferase fragment complementation and validated on the SARS-CoV-2 3CLpro model. The optimal luciferase variant incorporating the VLQSGF proteolytic site (Luc III) retained 88% of its native activity. A critical requirement for system performance was the use of an extended nsp4-nsp6 fragment of the viral polyprotein rather than the mature protease, underscoring the importance of the native context for 3CLpro activity. The bicistronic construct pCAG-Luc-III-IRES-nsp4-6 enables coordinated expression of the reporter and protease, thereby increasing assay reproducibility. IC

Indexed as

Antiviral AgentsBetacoronavirusCoronavirus 3C ProteasesLuciferasesProtease InhibitorsSARS-CoV-2AnimalsAzabicyclo CompoundsFluorescence Resonance Energy TransferHigh-Throughput Screening AssaysHumansLactamsLeucineLuciferases, FireflyPyrrolidinonesReproducibility of Results3C-like proteinase, SARS-CoV-2Antiviral AgentsAzabicyclo CompoundsCoronavirus 3C ProteasesGC376LactamsLeucineLuciferasesLuciferases, FireflynirmatrelvirProtease InhibitorsPyrrolidinonesSulfonic Acids3CLproantiviral inhibitorhigh-throughput screeningluciferaseSARS-CoV-2viral proteases

Identifiers

PMID42187449
PMCPMC13204911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.